Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global contact lenses for myopia control market was valued at USD 1.23 billion in 2023 and is projected to reach USD 2.14 billion by 2031, exhibiting a CAGR of 7.2% during the forecast period. This growth is primarily driven by the rising global prevalence of myopia, particularly among children and young adults, which has accelerated demand for effective control solutions beyond simple vision correction.
Contact lenses for myopia control represent a specialized segment of the ophthalmic lens industry, focused on slowing myopia progression rather than merely correcting refractive errors. These lenses work primarily through peripheral defocus technology, creating specific optical patterns that reduce strain on the eye's elongation mechanism. The market is dominated by multifocal designs, though orthokeratology (ortho-k) lenses are growing at a faster rate due to their non-invasive nature and high efficacy rates exceeding 50% in clinical studies.
Market growth is further accelerated by technological advancements in lens materials and designs, with major players like Johnson & Johnson Vision and CooperVision investing heavily in R&D. The Asia-Pacific region, particularly China, represents both the largest market and the fastest growing region, owing to its large population and rapidly increasing myopia prevalence approaching 90% among urban youth. Regulatory approvals for myopia control indications, particularly from the U.S. FDA and European CE marking, have significantly expanded market access in recent years.
Market analysis indicates a shift toward combination therapies, where contact lenses are used alongside other interventions like low-dose atropine. The average price point remains between USD 800-1200 per year per patient in developed markets, though costs vary significantly based on region and healthcare system structure. Market fragmentation remains moderate, with the top five manufacturers holding approximately 65% of the total market share as of 2023.
Rising Global Prevalence of Myopia
The increasing incidence of myopia worldwide, particularly among younger populations, is driving demand for effective control solutions. With over 2.2 billion people affected globally, the need for non-invasive solutions like contact lenses is accelerating market growth.
Growing Awareness and Diagnostic Capabilities
Healthcare providers are increasingly equipped with advanced diagnostic tools that enable early detection of myopia progression. This early intervention approach is driving adoption of specialized contact lenses as a preventive measure rather than just a corrective solution.
The global myopia management market is projected to reach $15.8 billion by 2028, growing at 9.7% CAGR
Rising healthcare expenditure in emerging economies enables greater access to advanced myopia control solutions, while technological advancements in lens materials and designs continue to improve efficacy and comfort.
MARKET CHALLENGES
High Treatment Costs and Accessibility
Specialized myopia control contact lenses carry significantly higher price points compared to standard corrective lenses, creating barriers for widespread adoption. In many regions, insurance coverage for these specialized lenses remains limited or non-existent.
Other Challenges
Regulatory Hurdles and Standardization
Differing regulatory requirements across countries create challenges for manufacturers seeking global market penetration. The lack of standardized testing protocols for myopia control efficacy makes comparative analysis challenging for both practitioners and patients.
Limited Professional Training and Awareness
Many eye care professionals lack specialized training in myopia management, creating a gap between available technology and practitioner readiness. This knowledge gap slows adoption rates and limits market expansion despite growing product availability.
Untapped Emerging Markets
Developing regions with large youth populations represent significant growth opportunities. Countries across Asia and Latin America show increasing myopia rates but currently low penetration of advanced control solutions, indicating substantial market potential.
Advancements in material science are enabling development of next-generation lenses with enhanced oxygen permeability while maintaining myopia control properties. These innovations open new market segments and application possibilities.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Orthokeratology Lenses demonstrate significant traction owing to their overnight usage model that doesn't interfere with daytime activities, while multifocal soft lenses gain popularity for their comfort and continuous myopia control, supported by clinical evidence of efficacy across diverse patient demographics. |
| By Application |
|
Pediatric Myopia Management remains the dominant application segment, driven by growing global awareness among parents and eye care professionals about early intervention importance, while young adult and professional athlete segments show increasing adoption due to lifestyle compatibility and performance benefits. |
| By End User |
|
Hospitals and Eye Clinics lead in adoption, offering integrated care pathways that combine myopia control lenses with comprehensive eye health services, while specialized centers develop deeper expertise in measurement technologies and treatment personalization that drives better patient outcomes. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
CooperVision leads the market with its MiSight 1 day soft contact lens, holding significant market share through its dual-focus design that simultaneously corrects vision and slows myopia progression. The company's strong clinical trial data and global distribution network provide competitive advantage.
Johnson & Johnson Vision follows closely with its ACUVUE brand, offering innovative myopia management solutions through advanced lens materials and designs. Their extensive R&D investments and strategic partnerships with eye care professionals strengthen their market position globally.
Alcon Inc. competes aggressively with its PRECISION1 for ASTIGMATISM and other vision correction solutions, investing heavily in next-generation myopia control technologies and international market expansion. Recent FDA approvals have accelerated their market penetration.
Bausch + Lomb maintains competitive positioning through its PureVision2 and other specialty lens portfolios, focusing on comfort and oxygen permeability enhancements. Their focus on patient-specific solutions drives steady market growth.
List of Key Contact Lenses For Myopia Control Companies ProfiledCooperVision (United States)
CooperVision (United States)
Johnson & Johnson Vision (United States)
Johnson & Johnson (United States)
Alcon Inc. (Switzerland)
Bausch + Lomb (Canada)
Specialized contact lenses for myopia control are experiencing rapid adoption, with market analysts projecting a 35% year-over-year growth in the specialized lens segment. Leading manufacturers are investing heavily in R&D to develop lenses that not only correct vision but also actively slow myopia progression, with recent clinical trials showing up to 59% reduction in progression rates.
Other TrendsOrthokeratology Lenses Dominate Premium Segment
Ortho-k lenses continue to capture the premium market segment, with recent data showing they account for 42% of all myopia control lens prescriptions in developed markets. The technology has evolved to include advanced breathability materials that allow for extended overnight wear while maintaining corneal health, contributing to their 28% market share growth in the past year.
Multi-focal contact lenses specifically designed for children have shown remarkable market penetration, with manufacturers reporting a 67% increase in pediatric fittings. These designs incorporate both distance and near vision correction while incorporating myopia control technology, making them particularly popular for children who require vision correction while managing myopia progression. The segment has grown to represent an estimated $1.2 billion in annual revenue globally.
Market analysis indicates that combination therapies, where myopia control lenses are used alongside other interventions, now represent approximately 30% of all myopia management cases in clinical settings. This trend is particularly strong in Asian markets where myopia prevalence is highest, with countries like China and South Korea showing the fastest adoption rates for advanced myopia control lenses.
Regional Analysis: Contact Lenses For Myopia Control MarketNorth America
North America represents the second largest market after Asia-Pacific, with particularly strong adoption in the United States where myopia affects approximately 40% of the population. The region benefits from well-established optometry infrastructure that facilitates both initial fitting and the critical follow-up adjustments required for successful myopia control. Cultural acceptance of specialized medical devices over simple vision correction creates willingness to invest in these solutions. The market shows strong growth particularly in metropolitan areas where specialized practitioners cluster, though rural access remains limited by availability of trained practitioners rather than demand factors.
Europe
Europe shows a diverse adoption pattern across its regions, with Northern countries generally displaying higher utilization rates than Southern and Eastern regions. The difference stems from both economic factors and healthcare system differences, with some national health systems offering partial coverage that removes financial barriers. Europe's aging optometrist population creates both challenges in knowledge transfer and opportunities for younger practitioners to specialize in this growth area. Regulatory harmonization continues to improve, though national differences in approval timelines remain a consideration for manufacturers.
Latin America
Latin America represents an emerging rather than mature market, with awareness and adoption still growing rather than plateauing. The region's younger population demographics create natural future demand as myopia incidence increases with lifestyle changes. Economic development remains uneven, creating both challenges in affordability and opportunities as economies develop. The region's generally stronger family structures compared to other regions can facilitate better adherence to treatment regimens when properly educated on importance.
Global Standards & Research
International standards development increasingly recognizes myopia control as distinct from simple vision correction, creating clearer regulatory pathways than five years ago. Global research initiatives increasingly focus on prevention rather than correction alone, with significant funding now directed at understanding myopia progression mechanisms. Professional organizations worldwide have updated their guidelines to include myopia management recommendations rather than solely vision correction. These changes create foundation for market growth as healthcare systems increasingly view myopia control as part of eye health rather than optional enhancement.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global contact lenses for myopia control market was valued at US$ 891 million in 2024 and is projected to reach US$ 1,298 million by 2031.
Which key companies operate in Global Contact Lenses For Myopia Control Market?
-> Key players include CooperVision, HOYA Vision Care, Johnson &Johnson Vision Care, Ovctek, EUCLID, and Menicon, among others.
-> Key growth drivers include increasing myopia prevalence, technological advancements in lens design, and growing awareness of myopia control benefits.
-> Asia-Pacific is the fastest-growing region, while North America remains a dominant market.
-> Emerging trends include customized lens designs, digital integration for patient monitoring, and sustainable manufacturing practices.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates